Possible role of Helicobacter pylori infection via microvascular dysfunction in cardiac syndrome X

Cardiology Journal

Volumn 16, Issue 6, 2009, Pages 585-587

  Rasmi, Yousef ^a   Raeisi, Sina ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiac syndrome X; Endothelial; Helicobacter pylori; Inflammation; Microvascular dysfunction

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; MICROANGIOPATHY; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; SYNDROME X;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICROVASCULAR ANGINA; MICROVESSELS;

EID: 74249097310     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (26)

1. Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: New concepts in prognosis and treatment. Am J Med, 2006; 119: 560-566.
2. Eskandarian R, Malek M, Mousavi SH, Babaei M. Association of Helicobacter pylori infection with cardiac syndrome X. Singapore Med J, 2006; 47: 704-706.
3. Kaski JC, Valenzuela Garcia LF. Therapeutic options for the management of patients with cardiac syndrome X. Eur Heart J, 2001; 22: 283-293.
4. Nocente R, Gentiloni N, Cremonini F et al. Resolution of syndrome X after eradication of virulent CagA-positive Helicobacter pylori. South Med J, 2000; 93: 1022-1023.
5. Beier D, Frank R. Molecular characterization of two-component systems of Helicobacter pylori. J Bacteriol, 2000; 182: 2068-2076.
6. Kanbay M, Kanbay A, Boyacioglu S. Helicobacter pylori infection as a possible risk factor for respiratory system disease: A review of the literature. Respir Med, 2007; 101: 203-209.
7. Oshima T, Ozono R, Yano Y et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol, 2005; 45:1219-1222.
8. De Meyer GR, Herman AG. Vascular endothelial dysfunction. Progress Cardiovasc Diseas, 1997; 39: 325-342.
9. Shahabi S, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. Immunol Cell Biol, 2008; 86: 175-178.
10. Baek HY, Lim JW, Kim H et al. Oxidative-stress-related proteome changes in Helicobacter pylori-infected human gastric mucosa. Biochem J, 2004; 379: 291-299.
11. Arroyo-Espliguero R, Mollichelli N, Avanzas P et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J, 2003; 24: 2006-2011.
12. Kanbay M, Gur G, Yucel M, Yilmaz U, Boyacioglu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci, 2005; 50: 1228-1231.
13. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98: 839-844.
14. Ross R. Atherosclerosis: An inflammatory disease. NEJM 1999; 340: 115-126.
15. Lanza GA. Cardiac syndrome X: A critical overview and future perspectives. Heart, 2007; 93: 159-166.
16. Cosin-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol, 2003; 41: 1468-1474.
17. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: Role of superoxide dismutase activity. Circulation, 2004; 109: 53-58.
18. On YK, Park R, Hyon MS, Kim SK, Kwon YJ. Are low total serum antioxidant status and elevated levels of C-reactive protein and monocyte chemotactic protein-1 associated with cardiac syndrome X? Circ J, 2005; 69: 1212-1217.
19. Arroyo-Espliguero R, Kaski JC. Microvascular dysfunction in cardiac syndrome X: The role of inflammation. CMAJ, 2006; 174: 1833.
20. Lanza GA, Luscher TF, Pasceri V et al. Effects of atrial pacing on arterial and coronary sinus endothelin-1 levels in syndrome X. Am J Cardiol, 1999; 84: 1187-1191.
21. Tousoulis D, Davies GJ, Asimakopoulos G et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol, 2001; 24: 301-304.
22. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 2000; 102: 1000-1006.
23. Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium - dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension, 1995; 25: 201-206.
24. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002; 105: 1890-1896.
25. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. NEJM, 1993; 328: 1659-1664.
26. Quyyumi AA, Cannon RO, 3rd, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation, 1992; 86: 1864-1871.